Status:
COMPLETED
Buprenorphine Dosing Interval - 5
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Conditions:
Opioid-Related Disorders
Eligibility:
All Genders
21-50 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to explore the feasibility of extending the dosing interval of well maintained buprenorphine patients to 48 and 72 hours, leading to eventual 3 times/week dosing.
Eligibility Criteria
Inclusion Criteria:
M/F ages 21-50. Opiate dependence according to DSM-IV critera. Self-reported use within the last 30 days. Agreeable to conditions of study and signed informed consent.
Exclusion Criteria:
Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nursing women. Dependence on ETOH or benzodiazepines or other sedative-hynotics. Acute hepatitis. Other medical conditions that deem participation to be unsafe.
Key Trial Info
Start Date :
November 1 1992
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00000209
Start Date
November 1 1992
Last Update
August 17 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Friends Research Institute
Los Angeles, California, United States, 90025